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Introduction. High-Dose-Rate brachytherapy (HDR-B) associatedwith image-guided radiation therapy (IGRT) allows dose escalation
of treatment to provide better disease control. To reduce side-effects to the patient, dose escalation requires incorporation
of techniques to ensure that treatment reproducibility (IG) and precision (HDR) are maintained. The goal of this work is to
preliminarily assess the initial acute and late toxicity associated by IGRT accompanied with HDR-B in our center.
Material and methods. Patients (p) with high-risk NCCN criteria were included in the study following-MRI evaluation. All patients
received a 3 cm long intraprostatic ﬁducial marker. The RT was planned with IMRT or 3D in patients with bladder ﬁlling of 500 cm3
and an empty rectum. The dose was administered with daily IGRT with respect to the ﬁducial marker. All patients received 45Gy
pelvic nodal irradiation and a prostatovesicular boost of 54Gy. After one week, an ultrasound-guided intraoperative HDR-B
(S.Swift, Nucletron®) was performed. An implant was placed and two fractions of 7Gy were administered. Before the evening
treatment, a re-planning was performed. During the two sessions, the bladder was ﬁlled with Cytistat®. IPSS at the moment of
the diagnosis was collected and toxicity was assessed according to the CTCAE-v4.0 scale at 3, 6, 12 months and then every 6
months.
Results. 57p were included: T1c: 12p (21%), T2ab: 12p (21%), T2c: 20p (35%) T3a: 13p (23%). Gleason: 6: 5p (9%), 7: 23p (40%) 8–10: 29p
(51%). Median follow-up: 16.4m. Maximum toxicity: Urinary frequency: G1: 1p (1.8%), G2: 5p (8.8%); Nocturia: G1: 15p (26.3%), G2:
3p (5.3%), G3: 1p (1.8%); Incontinence G0: 55p (94.5%), G1: 2p (3.5%). No p presented rectal ulcer, rectal incontinence or urethral
structure.
Conclusions. • HDR brachytherapy associated with IGRT allows raising RT dose with excellent tolerance in patients with prostate
carcinoma. • The use of Cytistat during HDR-B reduces initial acute and late urinary toxicity.
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